Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
Apellis Pharmaceuticals to Present at the 40th Annual Cowen Health Care Conference
Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
for paroxysmal nocturnal hemoglobinuria, geographic atrophy,
C3 glomerulopathy, and cold agglutinin disease.
are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.CLINICAL TRIALS